ORGO · Organogenesis Holdings Inc.
$1.31
-0.02 (-1.50%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$181.43M
Shares
128.67M
Volume · Oct 5
540.91K
Avg daily vol (3M)
752.18K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.33
Open$1.40
Day$1.32–1.40
52W close$1.33–6.54
Avg vol 30d632K
Short int14.1M · 11.0% float · 18.8d
Short vol74%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 3 wks
filed Aug 6, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$457.45M
Trailing 12 months
Net income (TTM)
−$84.16M
Trailing 12 months
Revenue growth YoY
-56.7%
Year over year
Operating margin
-7.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
11.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
-68.6%
Trailing year
Short interest
11.0%
Latest settlement · 18.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−52%
below
Price vs 50-day avg
−25%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−44%
trailing
YTD return
−74%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.97% of float · ▼ -0.9% MoM · 18.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
65%
contracting
EPS growth
+1600%
Y/Y
Free cash flow
$-24.5M
Balance sheet
$37.3M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total net revenue
· For the year ending December 31, 2026
Initiated
$179M – $215M
prior FY $564.17M
midpoint −65.1% Y/Y
Guided vs delivered
· last 2 settled
Net revenue
year ending December 31, 2023
guided $433M – $446M
$433.14M
In line
Net revenue
12 months ended December 31, 2021
guided $458M – $470M
$467.36M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−52%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.97% of float · ▼ -0.9% MoM · 18.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $7
vs 200-day avg -52%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$34.37M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP EBITDA -46.92M
+3.05M Stock-based compensation expense
+0K Inventory write-downs (2)
+5.1M Restructuring charge (3)
-1.19M Fair value adjustment to assets held for sale (4)
+5.59M R&D program termination costs (5)
= Adjusted EBITDA -34.37M
|
|||
| Adjusted EBITDA loss non-GAAP | $82.5M | the six months ended June 30, 2026 | — |
| Adjusted net loss non-GAAP | $132.8M | the six months ended June 30, 2026 | — |
| EBITDA non-GAAP | -$46.92M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -96.27M
-138K Interest income, net
+45.39M Income tax (benefit) expense
+3.67M Depreciation and amortization
+433K Amortization of intangible assets (1)
= EBITDA -46.92M
|
|||
| Non-GAAP operating loss non-GAAP | $97.1M | the six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORGO
this stock
Organogenesis Holdings Inc.
|
$181.43M | -74.3% | +17.0% | — | 11.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORGO | -5.7% | -18.9% | -44.1% | -2.9% | -74.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.5% | -18.4% | -56.3% | -3.8% | -87.2% |